Galapagos NV (AMS:GLPG)

Market Cap	1.81B
Revenue (ttm)	275.61M
Net Income (ttm)	-284.27M
Shares Out	65.90M
EPS (ttm)	-4.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,348
Average Volume	134,787
Open	27.60
Previous Close	27.50
Day's Range	26.90 - 27.60
52-Week Range	20.00 - 32.74
Beta	0.06
RSI	39.83
Earnings Date	Nov 5, 2025

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 704
• Stock Exchange: Euronext Amsterdam
• Ticker Symbol: GLPG

Financial Performance

In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.